Full history for every metric is available with a Kvantra account
AegirBio AB (publ) (AEGIR.ST)
Key financial summary
Financials in SEK| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | SEK m | - | 0 | 0 | 13 | 2 | 0 |
| Operating profit | SEK m | -56 | |||||
| Net profit | SEK m | - | -0 | -10 | -92 | -363 | -60 |
| EPS reported | SEK | -2.38 | |||||
| Operating cashflow per share | SEK | -1.68 | |||||
| Capex per share | SEK | 0.22 | |||||
| FCF per share | SEK | -1.90 | |||||
| Free cash flow | SEK m | -48 | |||||
| Net debt | SEK m | 20 | |||||
| Book value equity | SEK m | -1 | |||||
| Book value per share | SEK | -0.06 | |||||
| Number of shares | m | 25.05 | |||||
| DPS (TTM paid) | SEK | 0.00 |
Financial summary
Financials in SEK| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | -20.17 | |||||
| P/S LTM | x | 318.62 | |||||
| P/FCF LTM | x | -0.62 | |||||
| EV/EBITDA LTM | x | -1.13 | |||||
| EV/Sales LTM | x | 542.33 | |||||
| Earnings Yield LTM | % | -203.65% | |||||
| FCF Yield | % | -162.13% | |||||
| Quality | |||||||
| ROE | % | 4108.5% | |||||
| ROIC | % | -126.33% | |||||
| Operating margin | % | -61041.3% | |||||
| Gross margin | % | 47.83% | |||||
| FCF/Sales | % | -51657.6% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | -94.61% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | -1.45 | |||||
| Net Debt/EBITDA | x | -0.47 | |||||
| EBIT/Net interest | x | -5.62 | |||||
| Net debt/market cap | % | 68.70% | |||||
| Net debt/Equity | x | -13.86 | |||||
| Gross debt/equity | x | -22.52 | |||||
Company overview
AegirBio AB (publ) is a diagnostics firm established in 2019 in Lund, Sweden. The company specializes in developing and commercializing tests primarily aimed at monitoring the dosage of biological drugs. Their efforts are concentrated on therapeutic drug monitoring for biologic therapies across various conditions, including multiple sclerosis, different types of cancer, and autoimmune diseases. Among their offerings are moNATor, a pioneering laboratory test designed for dose monitoring in multiple sclerosis for both medical professionals and patients, and Viraspec, a saliva-based test kit for COVID-19 detection.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
AegirBio AB (publ) (AEGIR.ST)
AegirBio AB (publ) is a diagnostics firm established in 2019 in Lund, Sweden. The company specializes in developing and commercializing tests primarily aimed at monitoring the dosage of biological drugs. Their efforts are concentrated on therapeutic drug monitoring for biologic therapies across various conditions, including multiple sclerosis, different types of cancer, and autoimmune diseases. Among their offerings are moNATor, a pioneering laboratory test designed for dose monitoring in multiple sclerosis for both medical professionals and patients, and Viraspec, a saliva-based test kit for COVID-19 detection.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free